“Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion protein that binds A and B isoforms of VEGF and placental growth factor, thereby inhibiting angiogenesis. We assessed whether the addition of aflibercept to docetaxel and prednisone would improve overall survival in men with metastatic castrate-resistant prostate cancer compared with the addition of placebo to docetaxel and prednisone.”
In a recent clinical study, the prostate cancer drug enzalutamide decreased prostate-specific antigen (PSA) blood levels by an average of 99.6% in patients with prostate cancer who had not previously been treated with hormone therapy. Of the 67 patients involved in the study, 93% had a decline in PSA levels. Enzalutamide is an androgen receptor blocker that is currently approved by the FDA to treat men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with the chemotherapy drug docetaxel. The study results suggest that the drug may be an effective initial treatment for men with locally advanced prostate cancer, without the unwanted side effects associated with current hormone treatments known as androgen deprivation therapy.